Neuromed Licenses Phase 3 Chronic Pain Product from ALZA Corporation

26-Apr-2007

Neuromed Pharmaceuticals Ltd. announced that it has licensed from ALZA Corporation the exclusive U.S. rights to develop and commercialize OROS(R) Hydromorphone, an extended release formulation of a potent opioid analgesic in Phase 3 clinical development.

Under the terms of the agreement Neuromed will make an upfront payment of $30 million, additional regulatory milestone payments, and will pay royalties based on commercial sales of the product. Neuromed will develop and market the product in the U.S., while ALZA will retain the rights to develop and market the product in other countries. ALZA will manufacture the product for Neuromed as well as for other markets in which the product is sold.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...